Oncology Companion Diagnostic Market to grow to USD 10.60 billion by 2032 with a CAGR of 11.09%
This report points to the increasing incidence and prevalence of cancer by type and region, fueling the increasing use of companion diagnostics for tailored treatment strategies. The research analyzes healthcare expenditure on oncology diagnostics by different funding streams, such as government, commercial, private, and out-of-pocket spending, with a focus on regional differences in investment.